Gaithersburg, Md.—November 2, 2015 — VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary vaccine technology, announced that its Chief Executive Officer, Dr. Wataru Akahata, will present at the International Conference on Vaccines Research and Development 2015 on Tuesday, November 3, 2015, at 4:00 p.m. Eastern Time. The event will take place at the DoubleTree by Hilton Baltimore-BWI Airport in Linthicum, Maryland.
The following will be presented by Dr. Akahata at the Conference:
“Development of a Malaria Vaccine using an Alphavirus Virus-Like Particle (i-αVLP) Platform” – Track B at Harbor Room, Tuesday, November 3, 2015, 4:00pm – 4:20pm
About VLP Therapeutics
VLP Therapeutics, LLC (VLP) was established in 2012 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) technology platform. VLP is currently developing preventative and therapeutic vaccines as well as next generation of targeted antibody agents to treat cancer, infectious diseases, auto-immune diseases and neurological diseases.